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Abstract In the past year, a number of important pa-
pers have been published on non-ST-elevation acute
coronary syndrome, highlighting progress in clinical
care. The current review focuses on early diagnosis
and risk stratification using biomarkers and advances
in intracoronary imaging.
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Introduction
In addition to some universal clinical markers of
risk, such as advanced age, diabetes and renal in-
sufficiency, the initial clinical presentation is highly
predictive of early prognosis in patients with non-
ST-elevation acute coronary syndrome (NSTE-ACS).
Guidelines recommend the quantitative assessment
of ischaemic risk by means of risk scores such as the
GRACE score, which is superior to clinical assessment
alone. The GRACE risk score includes age, systolic
blood pressure, pulse rate, serum creatinine, Killip
class at presentation, cardiac arrest at admission, el-
evated cardiac biomarkers and ST deviation on the
electrocardiogram. A number of important papers
have been published in the past year highlighting
progress in early diagnosis and risk stratification.
The current review focuses on the use of biomark-
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ers and intracoronary imaging. As a celebration of
the European Society of Cardiology 2020 congress we
will discuss important upcoming or published Dutch
studies related to these subjects.
Biomarkers in diagnosis and risk stratification of
NSTE-ACS
In patients with chest pain, one of the main diag-
nostic concerns is whether the chest pain is due to
an acute coronary syndrome (ACS). In suspected ACS,
the diagnostic foundation is a combination of a 12-
lead electrocardiogram (ECG), clinical evaluation and
cardiac troponin measurements [1]. After obtaining
an ECG, the diagnosis is relatively straightforward in
patients with an acute ST-segment-elevation myocar-
dial infarction (STEMI). However, when ST-segment
elevations are absent on the ECG, further evaluation
is required in order to rule in or rule out an NSTE-ACS.
Although only 10–20% of chest pain patients have
an ACS, chest pain is one of the main complaints in
the emergency department (ED), accounting for up to
10% of all ED visits [2–7]. Moreover, ED overcrowd-
ing, which is associated with worse patient outcomes,
is a growing phenomenon [8, 9]. Therefore, early risk
stratification and a shorter time to diagnosis in chest
pain patients is important.
0h/1h algorithm
Measuring cardiac troponin with sensitive or high-
sensitivity cardiac troponin (hs-cTn) assays to rule in
or rule out NSTE-ACS is recommended by the Euro-
pean Society of Cardiology (ESC) [1]. If hs-cTn assays
are available, using a 0h/1h algorithm as an alter-
native to the 0h/3h algorithm is also recommended.
Using a 1-hour algorithm may reduce the delay to di-
agnosis, leading to shorter stays in the ED, less over-
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crowding and lower costs [10–15]. The applicability
and validity has recently been investigated in several
studies.
Boeddinghaus et al. evaluated the validity of the
0h/1h algorithm by prospectively enrolling patients
presenting to the ED with symptoms suggestive of
acute myocardial infarction in three diagnostic stud-
ies according to age (<55 years, ≥55 to <70 years, and
≥70 years). Hs-cTn T and hs-cTn I plasma concentra-
tions were measured at presentation and after 1h. In
all age groups, the rule-out safety was very high, with
a sensitivity of >99.3%.[16] However, with increasing
age, the overall specificity and the accuracy of rule-
in significantly decreased. Therefore, Boeddinghaus
et al. suggest that alternative slightly higher cut-off
concentrations may be considered for older patients.
The authors confirmed their findings in two validation
cohorts. However, when age is incorporated in the al-
gorithm in order to improve the specificity, adding
other confounders such as chronic kidney disease,
chronic heart failure and atrial fibrillation should also
be considered [17]. Twerenbold et al. evaluated the
real-world performance of the 0h/1h algorithm and
confirmed its excellent applicability [18]. The routine
use of the 0h/1h algorithm resulted in very low 30-
day major adverse cardiac event (MACE) rates in the
rule-out group and in outpatients (0.2% and 0.1%, re-
spectively). Moreover, routine use of the 0h/1h al-
gorithm resulted in an average short ED stay of 2.5h,
suggesting that implementation of the 0h/1h algo-
rithm might help to prevent ED overcrowding. Chew
et al. evaluated the 0h/1h algorithm in a randomised
setting in the RAPID-TnT trial.[19] In this multicentre
trial, patients with suspected ACS were randomised to
either the 0h/1h hs-cTn algorithm or the 0h/3h stan-
dard algorithm in which the troponin T assay’s high-
sensitivity performance characteristics were masked.
Patients randomised to the 0h/1h arm were more
likely to be discharged from the ED, had a shorter
length of stay in the ED and underwent less functional
cardiac testing. The negative predictive value of the
0h/1h algorithm was 99.6% for MACE.
To summarise, several studies have shown that
the 0h/1h algorithm recommended by the ESC is
an excellent fast rule-in and rule-out tool enabling
more rapid discharge and less additional testing in
suspected ACS patients.
Pre-hospital rule out
Ruling out ACS in the pre-hospital setting could have
major medical and economic value. Schols et al. con-
ducted a nationwide flash-mob study in the Nether-
lands to evaluate the safety of theMarburg Heart Score
(MHS) to rule out ACS [20]. The MHS is a clinical de-
cision rule based on five signs and symptoms, which
was designed to identify patients with a low proba-
bility of ACS as the underlying cause of chest pain in
the primary care population [21, 22]. Although rul-
ing out ACS in the primary care setting without ad-
ditional tests, such as the ECG and cardiac troponin
measurements, sounds attractive, Schols et al. showed
that ACS could not be safely ruled out using the MHS.
The FamouS Triage study group has shown that it is
possible to identify low-risk patients in the pre-hospi-
tal setting by assessing the modified History, Electro-
cardiogram, Age, Risk factors and Troponin (HEART)
score [23, 24]. Moreover, they have shown that incor-
porating a point-of-care (POC) troponin T test into the
HEART score enables ambulance paramedics to assess
the complete HEART score and rule out ACS in low-
risk patients at home [25]. In order to further evaluate
the possibilities of ruling out ACS at home, the ARTICA
(Acute Rule out of non-ST elevation acute coronary
syndrome in the pre-hospital setting by HEART score
assessment and a single poInt-of-CAre troponin) trial
is currently being conducted [26]. The ARTICA trial is
a randomised trial with a primary objective to evaluate
the cost-effectiveness of ruling out ACS at home. Low-
risk patients are identified by assessment of the H, E, A
and R components of the HEART score and then ran-
domised to either transfer to the ED (standard care)
versus POC troponin T measurement at home. If the
POC troponin T value is below the limit of detection
(40ng/l), an ACS is considered ruled out and the care
of the patient is transferred to the general practitioner.
Intracoronary optical coherence tomography for
diagnosis and risk stratification
Intracoronary imaging, using intravascular ultrasound
(IVUS) or optical coherence tomography (OCT) has
become widely implemented in the cathlab. Recently
a consensus document for the clinical use of intra-
coronary imaging in ACS was published, highlight-
ing several indications for OCT [27]. One of the key
roles for OCT in ACS is its ability to assist in identify-
ing a culprit lesion, based on the presence of throm-
bus. In the absence of significant coronary artery dis-
ease (CAD), OCT may assist in the evaluation of non-
atherosclerotic aetiologies. In addition to determining
the cause of an ACS, OCT enables in vivo assessment
of plaque composition. Determining the morphologi-
cal make-up of atherosclerotic lesionsmight help with
risk stratification by identifying high-risk plaques or
patients.
Dutch contribution to the field
 PECTUS trial on intracoronary imaging of vul-
nerable plaque.
 ARTICA trial on prehospital triage.
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OCT-derived vulnerable plaque features
Several characteristics of morphological lesions have
been associated with increased vulnerability to plaque
rupture in retrospective studies [28]. In general these
vulnerable lesions have a large necrotic core with
a thin, inflamed overlying fibrous cap, and are referred
to as thin-cap fibroatheromas. In the prospective ob-
servational CLIMA study, OCT-derived vulnerable
plaque features of lesions in the left anterior descend-
ing artery were correlated with a composite endpoint
of cardiac death and target segment myocardial in-
farction at 12-month follow-up [29]. It was shown
that lesions with the combination of four high-risk
features (a minimal lumen area of <3.5mm2, a fi-
brous cap thickness of <75µm, a lipid arc of >180°,
and macrophage infiltration) were associated with
the endpoint with a hazard ratio of 7.54. CLIMA was
the first OCT study to prospectively link plaque vul-
nerability to clinical endpoints. However, because
OCT imaging in this study was performed on a single
predefined segment, the question remains whether
‘targeted’ OCT imaging of angiographic lesions can
improve risk stratification, and potentially guide treat-
ment decisions. This gap in knowledge is currently
being addressed by the COMBINE (NCT02989740),
and PECTUS-obs study (NCT03857971).
Vulnerable plaque treatment
The ability to identify vulnerable coronary lesions
might have therapeutic consequences. In addition,
intracoronary imaging could be used to quantify vul-
nerability of the complete epicardial coronary system,
thereby identifying ‘vulnerable patients’. Aggressive
systemic therapy might be beneficial for vulnerable
plaques or patients. In addition, vulnerable plaques
might be a target for focal therapy by means of per-
cutaneous coronary intervention. Both systemic and
local therapies are the subject of multiple active stud-
ies. For instance, The HUYGENS (NCT03570697)
and PACMAN-AMI (NCT03067844) trials aim to see if
treatment with PCSK9 inhibition results in stabilisa-
tion of plaque morphology and fewer clinical events,
whereas the PROSPECT-ABSORB (NCT02171065) and
PREVENT (NCT02316886) studies focus on preventive
stenting of vulnerable plaques.
Healed plaques
Healed plaques are atherosclerotic lesions with a lay-
ered OCT appearance. This phenotype is believed
to be the result of repair processes of ruptured or
eroded plaques [30]. Identification of these lesions
with OCT has recently been validated against histol-
ogy and has gained considerable attention in the last
year [31]. In an observational cohort study of 105 pa-
tients who had undergone coronary angiography with
OCT imaging of non-culprit lesions, patients were di-
vided into two groups based on the two extremes of
the clinical spectrum of CAD [32]. The first group con-
tained patients who had long-standing stable CAD,
and the second group contained patients with a his-
tory of multiple recurrent ACS. In the long-term sta-
ble CAD group, healed plaques were seen in about
one-third of patients, whereas in the recurrent ACS
group hardly any healed plaques were observed. The
authors argued that plaque healing takes place after
plaque rupture or erosion if thrombosis-resisting fac-
tors prevail, whereas a clinically manifest ACS occurs
in a more pro-thrombotic environment, and that de-
tection of healed plaques could therefore help identify
patients who are relatively protected from developing
acute occlusive thrombosis. A different OCT study of
pre-intervention ACS culprit lesions showed a layered
phenotype in 29% of lesions [33]. In contrast to the
previous study, they found that patients with healed
culprit plaques were more often associated with a his-
tory of myocardial infarction. Additionally, plaque
rupture, lipid plaques, and thin-cap fibroatheromas
were more prevalent in healed culprit plaques and
the prevalence of healed plaques increased with an in-
creasing degree of percent area stenosis. The authors
therefore concluded that the associations with plaque
vulnerability may outweigh the protective mechanism
of plaque healing and might actually predispose pa-
tients to future acute coronary events. In a following
study of the same cohort of ACS patients, it was shown
that this association with vulnerable plaque character-
istics also extended to healed non-culprit lesions [34].
Future perspective
We have discussed recent developments in the diag-
nosis and risk stratification of NSTE-ACS. With regards
to the early diagnosis, multiple reports have shown
the diagnostic accuracy of the 0h/1h algorithm en-
abling earlier ruling in and ruling out of NSTEMI. We
expect improvements in the POC assays, resulting in
an even higher accuracy in the pre-hospital triage in
the ambulance or even by the general practitioner.
NSTE-ACS is associated with long-term recurrent is-
chaemic events. The concept of identifying vulnera-
ble plaques or patients based on the characteristics
of morphological lesions seems promising, and might
further improve risk stratification if added to existing
risk models. However, more prospective studies with
clinical outcome data are needed to validate this strat-
egy.
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